PeptiSystems strengthens its Board of Directors with Ole J. Dahlberg
- Apr 30
- 2 min read
30th of April, 2026 - Uppsala, Sweden
PeptiSystems, a life science company pioneering advanced manufacturing solutions for peptide and oligonucleotide drugs, has appointed Ole J. Dahlberg to its Board of Directors. The appointment reflects the company’s focus on scaling commercial operations and expanding its global presence.
PeptiSystems develops and commercializes flow-through synthesis instruments for peptide and oligonucleotide therapeutics. The instruments are used by pharmaceutical companies and CDMOs to improve production capacity, resource efficiency, and process control.
Ole J. Dahlberg brings more than 20 years of international leadership experience in the life science sector, including CEO roles in both growth-stage and established companies. He has held senior positions at Life Technologies, Qiagen, and Thermo Fisher Scientific, where he most recently served as Vice President and General Manager.
As Managing Partner at Rubicon Healthcare Partners, a major shareholder in PeptiSystems, Dahlberg brings both operational experience and an investor perspective to the Board. He also holds several board positions across the life science sector.
“We are scaling our commercial operations and expanding our global presence. Ole’s experience from international life science companies and global organizations will be valuable as we continue to grow the business. We are pleased to welcome him to the Board of Directors,” says Karin Granath, CEO of PeptiSystems.
For more information, please contact:
Karin Granath, CEO
Phone: +46 702-82 07 47
About PeptiSystems AB
PeptiSystems is a life science company developing a new generation of flow-through instruments for peptide and oligonucleotide therapeutics synthesis. Utilizing proprietary flow-through column technology, PeptiSystems' instruments significantly reduce production times, enhance synthesis control, and minimize raw material consumption while maintaining high purity and yield. With scalability in mind, these next-generation synthesis instruments seamlessly adapt from small-scale development to large-scale production, enabling pharmaceutical companies and CDMOs to meet the growing global demand for high-performance, cost-effective, and sustainable manufacturing processes. PeptiSystems is headquartered in Uppsala, Sweden. For more information, please visit www.peptisystems.com and follow us on LinkedIn.